Tandem Micro-Flow LC-MS Proteome Analysis of Urine and Plasma to Unravel Disease Mechanisms and Biomarker Discovery
The presentation focuses on advancements in proteomics and metabolomics, emphasizing robust, large-scale, and high-throughput analysis. Key points include the development of assays that operate 24/7 with minimal carryover and high dynamic range, essential for precision medicine.
The presentation highlights the importance of translating findings from human samples to preclinical and clinical models, aiding in target identification and biomarker discovery. It discusses the use of microflow and capillary flow rates to improve sensitivity and the application of multiple technologies to analyze plasma and other biofluids. Case studies, such as those involving respiratory distress syndrome patients, demonstrate the identification of proteins and pathways affected by treatments.
The presentation underscores the need for standardization in sample preparation and the integration of various proteomics technologies to enhance disease understanding and biomarker validation.
Learning points :
- Advancements in Proteomics and Metabolomics: Learn about the latest technologies and methodologies that enable large-scale, high-throughput, and robust proteomics and metabolomics analyses, essential for precision medicine.
- Translational Research Applications: Understand how findings from human samples can be translated to preclinical and clinical models, aiding in target identification, biomarker discovery, and disease mechanism elucidation.
- Standardization and Integration: Explore the importance of standardizing sample preparation and integrating multiple proteomics techniques to improve the accuracy and reliability of biomarker validation and disease understanding.
Who should attend?
- Translational Scientists and Researchers: Those involved in drug development, target identification, and precision medicine will benefit from understanding the latest advancements in proteomics and metabolomics for translating findings from human samples to preclinical and clinical models.
- Clinical and Preclinical Model Developers: Professionals working on developing and validating clinical and preclinical models to better understand disease mechanisms and identify new biomarkers will find the presentation valuable.
- Biomarker Discovery and Validation Experts: Individuals focused on the discovery and validation of biomarkers in biofluids and tissues, particularly those looking to standardize sample preparation and integrate multiple proteomics technologies, will gain important insights.
Additional Webinars
Take advantage of our growing library of convenient and educational recorded webinars and resources. Visit our webinars page
Presenter: Dr. Alexander Boychenko (Head of R&D Laboratory Precision Medicine Markers Bayer)
Alexander Boychenko is leading Omics Research within the Translational Sciences team of the Pharmaceuticals division at Bayer Group. He is focused on implementing innovative analytical technologies and developing novel methodologies for proteomics, metabolomics, and ligand-binding assays (LBA) to comprehensively characterize human and animal model phenotypes, enabling disease understanding and novel biomarker discovery. He holds a Ph.D. in Analytical Chemistry from Kharkiv National University, Ukraine. During his post-doctoral work at the University of Groningen, The Netherlands, he combined LC-MS and immunoassays to discover and validate protein biomarkers in biofluids for cancer screening. Before joining Research and Early Development at Bayer AG, he developed and introduced new liquid chromatography-mass spectrometry products at Thermo Fisher Scientific. Alexander is a subject matter expert in LC-MS, biological data interpretation, and precision medicine. He utilizes his passion for applying technical expertise to develop new medicines.
